3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Ovarian Neoplasms
4
Neoplasms
4
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Breast Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urinary Bladder Diseases
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Testicular Neoplasms
1
Interventions
umbralisib
1
ublituximab
1
marizomib
1
fludarabine phosphate
1
fludarabine
1
enzastaurin
1
durvalumab
1
carotuximab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
Zoledronic Acid
1
Vitamin D
1
Receptors, Interleukin-6
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Interleukin 1 Receptor Antagonist Protein
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
Cisplatin
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease Progression
×
durvalumab
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts